Vista Partners Updates Coverage on Raptor Pharmaceutical Corp. (NASDAQ: RPTP); Raises Target Price to $5.55

LOS ANGELES, Feb. 11 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceutical Corp. and raised its split adjusted twelve month target price to $5.55. Ross Silver, Principal Analyst for Vista Partners stated, "Raptor's current valuation is well below its peer group which does not make a lot of sense considering Raptor is currently involved in five Phase II clinical programs with some indications in multi-billion dollar markets. The recently closed $7.5M equity offering will enable the Company to move all of their principal clinical programs forward, with a primary focus on their lead compound, DR Cysteamine, for the treatment of cystinosis." Mr. Silver continued, "With a strong balance sheet, robust clinical pipeline and management team that has taken compounds from concept to approval twice already, we believe Raptor should trade at a premium to their peer group and as such we anticipate significant share price appreciation in 2010." For more information and to download the report for FREE, please visit the Vista Partners website at www.vistap.com and click on the "download research" icon or click here.

About Vista Partners:

With offices in California and Oregon, Vista Partners LLC is one of the fastest growing independently owned equity research and consulting firms in the United States. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners has built a name for itself in the small cap space due to its selection of profitable investment recommendations.

SOURCE Vista Partners

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED